Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

August 14, 2024

https://www.globenewswire.com/news-release/2024/08/13/2929115/0/en/Replimune-Announces-First-Patient-Dosed-in-IGNYTE-3-Clinical-Trial-in-Advanced-Melanoma.html

WOBURN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that the first patient has been randomized and dosed in the IGNYTE-3 study – a global Phase 3 clinical trial assessing the efficacy and safety of RP1 (vusolimogene oderparepvec) plus nivolumab in patients with advanced melanoma who have progressed on anti-PD1 and anti-CTLA-4 drugs or are ineligible for anti-CTLA-4 treatment.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.